PT  - JOURNAL ARTICLE
AU  - Tang, Keke
AU  - Huang, Yining
AU  - Chen, Meilian
TI  - Novel Coronavirus 2019 (Covid-19) epidemic scale estimation: topological network-based infection dynamics model
AID  - 10.1101/2020.02.20.20023572
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.20.20023572
4099  - http://medrxiv.org/content/early/2020/03/03/2020.02.20.20023572.short
4100  - http://medrxiv.org/content/early/2020/03/03/2020.02.20.20023572.full
AB  - Backgrounds An ongoing outbreak of novel coronavirus pneumonia (Covid-19) hit Wuhan and hundreds of cities, 29 territories in global. We present a method for scale estimation in dynamic while most of the researchers used static parameters.Methods We use historical data and SEIR model for important parameters assumption. And according to the time line, we use dynamic parameters for infection topology network building. Also, the migration data is used for Non-Wuhan area estimation which can be cross validated for Wuhan model. All data are from public.Results The estimated number of infections is 61,596 (95%CI: 58,344.02-64,847.98) by 25 Jan in Wuhan. And the estimation number of the imported cases from Wuhan of Guangzhou was 170 (95%CI: 161.27-179.26), infections scale in Guangzhou is 315 (95%CI: 109.20-520.79), while the imported cases is 168 and the infections scale is 339 published by authority.Conclusions Using dynamic network model and dynamic parameters for different time periods is an effective way for infections scale modeling.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received in this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were from the public.